康弘药业：关于公司收到药品注册证书的公告

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron sustained-release tablets from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [2] Group 1 - The drug registration certificate number is 2025S03430, which confirms the approval of Mirabegron sustained-release tablets [2]